In a filing, Beam Therapeutics Inc revealed its Chief Medical Officer Simon Amy unloaded Company’s shares for reported $17167.0 on Jul 02 ’24. In the deal valued at $22.95 per share,748 shares were sold. As a result of this transaction, Simon Amy now holds 68,805 shares worth roughly $1.72 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Simon Amy sold 502 shares, generating $11,928 in total proceeds. Upon selling the shares at $23.76, the Chief Medical Officer now owns 69,553 shares.
Before that, Evans John M. sold 60,000 shares. Beam Therapeutics Inc shares valued at $1,470,156 were divested by the CEO at a price of $24.50 per share. As a result of the transaction, Evans John M. now holds 998,343 shares, worth roughly $24.96 million.
H.C. Wainwright initiated its Beam Therapeutics Inc [BEAM] rating to a Buy in a research note published on July 23, 2024; the price target was $80. A number of analysts have revised their coverage, including JP Morgan’s analysts, who increased its forecast for the stock in late January from “a Neutral” to “an Overweight”. BofA Securities also remained covering BEAM and has decreased its forecast on December 15, 2023 with a “Neutral” recommendation from previously “Buy” rating. Jefferies revised its rating on December 08, 2023. It rated BEAM as “a Hold” which previously was an “a Buy”.
Price Performance Review of BEAM
On Monday, Beam Therapeutics Inc [NASDAQ:BEAM] saw its stock jump 2.33% to $25.00. Over the last five days, the stock has gained 4.25%. Beam Therapeutics Inc shares have fallen nearly -8.16% since the year began. Nevertheless, the stocks have risen 6.43% over the past one year. While a 52-week high of $49.50 was reached on 02/27/24, a 52-week low of $16.95 was recorded on 04/25/24. SMA at 50 days reached $25.75, while 200 days put it at $27.40.
Levels Of Support And Resistance For BEAM Stock
The 24-hour chart illustrates a support level at 24.37, which if violated will result in even more drops to 23.73. On the upside, there is a resistance level at 25.67. A further resistance level may holdings at 26.33. The Relative Strength Index (RSI) on the 14-day chart is 45.61, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.97, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 81.23%. Stochastics%K at 16.03% indicates the stock is a buying.
How much short interest is there in Beam Therapeutics Inc?
A steep rise in short interest was recorded in Beam Therapeutics Inc stocks on 2024-07-31, dropping by -0.17 million shares to a total of 11.62 million shares. Yahoo Finance data shows the prior-month short interest on 2024-06-28 was 11.8 million shares. There was a decline of -1.51%, which implies that there is a negative sentiment for the stock.
